Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered 'landmark' results, and the drug's safety profile has previously been one of its main potential selling points. But Wall Street was rattled by malignancy events that call this into question.
Abivax has proclaimed that its maintenance trial in ulcerative colitis delivered “landmark” results, and the drug’s safety profile has previously been one of its main …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concerns
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Why Is Abivax Stock Sinking Tuesday? - Abivax (NASDAQ:ABVX)
Abivax stock plunges on cancer signal in ulcerative colitis trial
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
Radiopharmaceutical shows promise in post-Pluvicto setting
Abivax share plunge may change deal outlook
A Parigi crolla Abivax, segnalati casi di cancro in studio clinico su farmaco
New cancer jab returns ‘unprecedented’ results in major clinical trial
Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares…
"The cancer signal complicates matters."
Abivax shares plunge more than 35% as cancer cases reported in a Phase 3 trial overshadow strong efficacy results for ulcerative…
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't…
Shares of French biotech Abivax tumbled 32% after it reported fresh data on its lead asset.
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as…
